111, Inc. (YI) stock plummeted 8.67% in the current-market trading session at the price of $2.95 despite no fundamental updates. The last published news was its earnings report for the fourth quarter and fiscal 2021.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
YI is a top Chinese technology-based healthcare firm that links patients with medication and healthcare services. The company offers customers better access to healthcare products and services via its online and offline retail pharmacy network.
YI Q4 2021 Financial Highlights
On 17th March 2022, YI announced its financial results for Q4 and the year ended on 31st December 2021. Revenues totaled RMB3.46B for Q4 of 2021. It represents a 30.9 percent gain from RMB2.64B for the same period of 2020.
Operating costs were RMB3.6B for Q4 of 2021, a 27.9 percent surge from RMB2.8B in Q4 of 2020. YI calculated an operating loss of RMB104.7 for Q4 of 2021. Operating loss totaled RMB144.7M for the same quarter of 2020. Net loss for Q4 of 2021 was RMB101.7M compared to a loss of RMB137.4M in Q4 of last year.
Fiscal 2021 Earnings Report
Revenues totaled RMB12.4B for fiscal 2021, representing a 51.5 percent gain from RMB8.2B prior year. The company has operating costs of RMB13.1B for 2021, a 50.6 percent rise from RMB8.7B the previous year. YI reported a net loss of RMB621M for fiscal 2021 compared to RMB467.1M in 2020.
Operations loss was RMB642.1M for fiscal 2021 compared to RMB473.3M prior year. As of 31st December 2021, cash and cash equivalents totaled RMB943.2M. The company has cash of RMB1.6B on 31st December 2020.
Collaboration Deal with Shenzhen BGI
Earlier on 14th March 2022, YI announced signing a strategic partnership deal with Shenzhen BGI. As per the agreement, BGI will deliver its Covid-19 antigen detection kits across China through YI’s online pharmacy network. The contract will facilitate nationwide prevention and control of the pandemic. 1 Pharmacy will evolve as the first digital retail platform for BIG’s Covid-19 kits.